Building a better vector: The manipulation of AAV virions

Virology

Volumn 278, Issue 2, 2000, Pages 301-308

  Rabinowitz, Joseph E ^a   Samulski, R Jude ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; SINGLE STRANDED DNA; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; AMINO ACID SEQUENCE; DNA MODIFICATION; GENE THERAPY; IMMUNE RESPONSE; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; SEROTYPE; SHORT SURVEY; VIRION;

ADENO-ASSOCIATED VIRUS;

EID: 0034531297     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.2000.0707     Document Type: Article

References (42)

1. Transfer of contaminants in adeno-associated virus vector stocks can mimic transduction and lead to artifactual results
2. Two amino acid substitutions within the capsid are coordinately required for acquisition of fibrotropism by the lymphotropic strain of minute virus of mice
3. Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors
4. 2 antibody
5. Serological evidence for human infection with adenovirus-associated viruses
6. A seroepidemiologic study of adenovirus-associated virus infections in infants and children
7. Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration
8. Multiple amino acids in the capsid structure of canine parvovirus coordinately determine the canine host range and specific antigenic and hemagglutination properties
9. Several log increase in therapeutic transgene delivery by distinct adeno-associated viral sero-type vectors
10. Cloning and characterization of adeno-associated virus type 5
11. Immune responses to adenovirus and adeno-associated virus in humans
12. Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle
13. Recombinant adeno-associated virus type 2, 4, and 5 vectors: Transduction of variant cell types and regions in the mammalian central nervous system
14. Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV)
15. New developments in the generation of Ad-free high titer rAAV gene therapy vectors
16. Recombinant adeno-associated virus for muscle directed gene therapy
17. Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type
18. Production of recombinant adeno-associated viral vectors and use in in vitro and in vivo administration
19. Transduction by adeno-associated virus vectors in the rabbit airway. Efficiency, persistence, and readministration
20. Successful readministration of adeno-associated virus vectors to the mouse lung requires transient immunosuppression during the initial exposure
21. Latent adeno-associated virus infection elicits humoral but not cell-mediated immune responses in a nonhuman primate model
22. Studies of small DNA viruses found in various adenovirus preparations: Physical, biological, and immunological characteristics
23. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers
24. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein
25. Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors
26. Adeno-associated virus general transduction vectors: Analysis of proviral structures
27. AAV vectors: Is clinical success on the horizon?
28. Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: Implications for gene therapy and virus structure
29. Insertional mutagenesis of AAV2 capsid and the protection of recombinant virus
30. Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2
31. Helper-free stocks of recombinant adeno-associated viruses: Normal integration does not require viral gene expression
32. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions
33. Intermediates of adeno-associated virus type 2 assembly: Identification of soluble complexes containing Rep and Cap proteins
34. Analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism
35. Gene therapy vectors based on adeno-associated virus type
36. Route of administration determines induction of T-cell-independent humoral responses to adeno-associated virus vectors
37. Efficient long term gene transfer into muscle tissue of immunocompetent mice by adenoassociated virus vector
38. Development of novel cell surface CD34-targeted recombinant adeno-associated virus vectors for gene therapy
39. Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilities gene transfer
40. CD40 ligand-dependent activation of cytotoxic T lymphocytes by adeno-associated virus vectors in vivo: Role of immature dendritic cells
41. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield